Small interfering RNA for cancer treatment: overcoming hurdles in delivery

Charbe NB 1 , Amnerkar ND 2 , Ramesh B 3 , Tambuwala MM 4 , Bakshi HA 4 , Aljabali AAA 5 Show all authors , Khadse SC 6 , Satheeshkumar R 1 , Satija S 7 , Metha M 7 , Chellappan DK 8 , Shrivastava G 9 , Gupta G 10 , Negi P 11 , Dua K 7 , Zacconi FC 1

Affiliations 

  • 1 Departamento de Quimica Orgánica, Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, Santiago 7820436, Chile
  • 2 Adv V. R. Manohar Institute of Diploma in Pharmacy, Nagpur, Maharashtra 441110, India
  • 3 Sri Adichunchunagiri College of Pharmacy, Sri Adichunchunagiri University, BG Nagar, Karnataka 571418, India
  • 4 School of Pharmacy and Pharmaceutical Science, Ulster University, Coleraine, Northern Ireland BT52 1SA, UK
  • 5 Faculty of Pharmacy, Department of Pharmaceutics and Pharmaceutical Technology, Yarmouk University, Irbid 21163, Jordan
  • 6 Department of Pharmaceutical Chemistry, R.C. Patel Institute of Pharmaceutical Education and Research, Dist. Dhule, Maharashtra 425 405, India
  • 7 Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, NSW 2007, Australia
  • 8 Department of Life Sciences, School of Pharmacy, International Medical University, Bukit Jalil 57000, Kuala Lumpur, Malaysia
  • 9 Department of Biochemical Engineering and Biotechnology, Indian Institute of Technology, Delhi, New Delhi 110016, India
  • 10 School of Pharmacy, Suresh Gyan Vihar University, Jagatpura, Jaipur 302017, India
  • 11 School of Pharmaceutical Sciences, Shoolini University of Biotechnology and Management Sciences, Solan 173229, India
Acta Pharm Sin B, 2020 Nov;10(11):2075-2109.
PMID: 33304780 DOI: 10.1016/j.apsb.2020.10.005

Abstract

In many ways, cancer cells are different from healthy cells. A lot of tactical nano-based drug delivery systems are based on the difference between cancer and healthy cells. Currently, nanotechnology-based delivery systems are the most promising tool to deliver DNA-based products to cancer cells. This review aims to highlight the latest development in the lipids and polymeric nanocarrier for siRNA delivery to the cancer cells. It also provides the necessary information about siRNA development and its mechanism of action. Overall, this review gives us a clear picture of lipid and polymer-based drug delivery systems, which in the future could form the base to translate the basic siRNA biology into siRNA-based cancer therapies.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications